Checkpoint Therapeutics announced “positive” preliminary safety and efficacy data from an ongoing Phase 1/2 clinical trial of CK-101, a third-generation epidermal growth factor receptor, or EGFR, tyrosine kinase inhibitor being evaluated in advanced non-small cell lung cancer. The data will be presented at the International Association for the Study of Lung Cancer, or IASLC.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.